These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38631081)

  • 21. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.
    Ferreira JJ; Lees AJ; Poewe W; Rascol O; Rocha JF; Keller B; Soares-da-Silva P
    Neurology; 2018 May; 90(21):e1849-e1857. PubMed ID: 29695590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A
    Rocha JF; Ebersbach G; Lees A; Tolosa E; Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Magalhães D; Gama H; Soares-da-Silva P
    Front Neurol; 2021; 12():754016. PubMed ID: 34803891
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
    Müller T; Schlegel E; Zingler S; Thiede HM
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
    Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations.
    Reichmann H; Eggert K; Oehlwein C; Warnecke T; Lees AJ; Kemmer M; Soares-da-Silva P
    Eur Neurol; 2022; 85(5):389-397. PubMed ID: 35350024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
    Olanow CW; Espay AJ; Stocchi F; Ellenbogen AL; Leinonen M; Adar L; Case RJ; Orenbach SF; Yardeni T; Oren S; Poewe W;
    J Parkinsons Dis; 2021; 11(1):177-186. PubMed ID: 33164945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Catalan MJ; Molina-Arjona JA; Mir P; Cubo E; Arbelo JM; Martinez-Martin P;
    J Neurol; 2018 Jun; 265(6):1279-1287. PubMed ID: 29557989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
    Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Cannas A; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Costanzo AM; Gualberti G; Melzi G; di Luzio Paparatti U; Antonini A
    Neurol Sci; 2016 Nov; 37(11):1785-1792. PubMed ID: 27421834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
    Hansen RN; Suh K; Serbin M; Yonan C; Sullivan SD
    J Med Econ; 2021; 24(1):563-569. PubMed ID: 33866942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A
    Rocha JF; Ebersbach G; Lees A; Tolosa E; Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Magalhães D; Gama H; Soares-da-Silva P
    Front Neurol; 2022; 13():994114. PubMed ID: 36081875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opicapone for Parkinson's disease: clinical evidence and future perspectives.
    Leung C; Rascol O; Fabbri M
    Neurodegener Dis Manag; 2021 Jun; 11(3):193-206. PubMed ID: 33745288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
    Cáceres-Redondo MT; Carrillo F; Lama MJ; Huertas-Fernández I; Vargas-González L; Carballo M; Mir P
    J Neurol; 2014 Mar; 261(3):561-9. PubMed ID: 24477490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
    Espay AJ; Stocchi F; Pahwa R; Albanese A; Ellenbogen A; Ferreira JJ; Giladi N; Gurevich T; Hassin-Baer S; Hernandez-Vara J; Isaacson SH; Kieburtz K; LeWitt PA; Lopez-Manzanares L; Olanow CW; Poewe W; Sarva H; Yardeni T; Adar L; Salin L; Lopes N; Sasson N; Case R; Rascol O;
    Lancet Neurol; 2024 May; 23(5):465-476. PubMed ID: 38499015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
    Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Moreira J; Guimarães B; Rocha JF; Soares-da-Silva P
    Mov Disord; 2022 Nov; 37(11):2272-2283. PubMed ID: 36054562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.